Key result
Shen-Yuan-Dan cuts periprocedural myocardial injury ~77% vs conventional treatment during elective PCI for unstable angina.
Why the study?
The study was conducted to investigate the effects of Shen-Yuan-Dan on periprocedural myocardial injury and peripheral blood endothelial progenitor cell counts in patients with unstable angina undergoing elective PCI.
Does Shen-Yuan-Dan reduce periprocedural myocardial injury and increase peripheral blood endothelial progenitor cells in patients with unstable angina pectoris undergoing elective percutaneous coronary intervention?
RCT (n=62)
Random number table method
Does Shen-Yuan-Dan reduce periprocedural myocardial injury and increase peripheral blood endothelial progenitor cells in patients with unstable angina pectoris undergoing elective percutaneous coronary intervention?
Shen-Yuan-Dan added to conventional therapy reduces periprocedural myocardial injury and promotes the mobilization of endothelial progenitor cells in patients with unstable angina undergoing elective PCI.
Answers are grounded in this paper and cite their sources.
Supports adjunctive Shen-Yuan-Dan to reduce periprocedural injury in unstable angina PCI; extends evidence for traditional Chinese medicine in interventional cardiology.
Objectives. We aimed to investigate the effects of Shen-Yuan-Dan (SYD), a Chinese medicine preparation, on periprocedural myocardial injury (PMI) and the number of peripheral blood endothelial progenitor cells (EPCs) in patients with unstable angina pectoris (UA) who underwent elective percutaneous coronary intervention (PCI). Methods. Patients were randomly divided into the experimental (group A) and control (group B) groups through the random number table method. In group A, patients concurrently received the conventional western treatment and SYD orally (4 capsules/time, 3 times/d, from 3 d before surgery to 7 d after surgery). In group B, patients received conventional Western medicine treatment. Both groups underwent coronary angiography, and patients undergoing PCI were eventually included in the study. The following patient data were collected: incidence of PMI, serum CK-MB content before PCI, 4 h, 24 h, and 7 d after PCI, number of CD45dim/-CD34+CD309+ peripheral venous EPCs, and number of CD184 coexpressed EPCs. The incidence of adverse reactions and 30-day major adverse cardiovascular events (MACEs) were also recorded. Results. Sixty-two patients were finally included in this study, with 32 and 30 in groups A and B, respectively. In group A, the number of peripheral blood EPCs and the number of CD184 coexpressed EPCs at 1 h before surgery were higher than those at 3 d before surgery (37.24 ± 25.20 vs. 22.78 ± 9.60/ml; <a:math xmlns:a="http://www.w3.org/1998/Math/MathML" id="M1"><a:mi>P</a:mi><a:mo><</a:mo><a:mn>0.001</a:mn></a:math> and 23.38 ± 15.30 vs. 13.54 ± 8.08/ml; <c:math xmlns:c="http://www.w3.org/1998/Math/MathML" id="M2"><c:mi>P</c:mi><c:mo><</c:mo><c:mn>0.001</c:mn></c:math> , resp.). The number of peripheral blood EPCs and number of CD184 coexpressed EPCs at 4 h after surgery were lower than those at 1 h before surgery (25.30 ± 11.90 vs. 37.24 ± 25.20/ml; <e:math xmlns:e="http://www.w3.org/1998/Math/MathML" id="M3"><e:mi>P</e:mi><e:mo>=</e:mo><e:mn>0.019</e:mn></e:math> and 15.38 ± 8.78 vs. 23.38 ± 15.30/ml; <g:math xmlns:g="http://www.w3.org/1998/Math/MathML" id="M4"><g:mi>P</g:mi><g:mo>=</g:mo><g:mn>0.013</g:mn></g:math> , resp.), but there was no difference at 24 h and at 7 d after surgery in comparison with that at 1 h before surgery ( <i:math xmlns:i="http://www.w3.org/1998/Math/MathML" id="M5"><i:mi>P</i:mi><i:mo>></i:mo><i:mn>0.05</i:mn></i:math> ). In group B, compared with that at 1 h before surgery, there existed a decline in the number of EPCs in peripheral blood and the number of CD184 coexpressed EPCs at 4 h after surgery, but without a statistical difference ( <k:math xmlns:k="http://www.w3.org/1998/Math/MathML" id="M6"><k:mi>P</k:mi><k:mo>></k:mo><k:mn>0.05</k:mn></k:math> ). Comparing both groups, it was found that the incidence of PMI in group A was lower (6.25% vs. 26.67%; <m:math xmlns:m="http://www.w3.org/1998/Math/MathML" id="M7"><m:mi>P</m:mi><m:mo>=</m:mo><m:mn>0.04</m:mn></m:math> ), and the serum CK-MB content at 4 and 24 h after surgery was also lower than that in group B (17.33 ± 5.83 vs. 20.38 ± 4.32 U/l; <o:math xmlns:o="http://www.w3.org/1998/Math/MathML" id="M8"><o:mi>P</o:mi><o:mo>=</o:mo><o:mn>0.048</o:mn></o:math> and 15.79 ± 5.32 vs. 19.10 ± 4.93 U/l; <q:math xmlns:q="http://www.w3.org/1998/Math/MathML" id="M9"><q:mi>P</q:mi><q:mo>=</q:mo><q:mn>0.030</q:mn></q:math> , resp.). The number of EPCs in peripheral blood and the number of CD184 coexpressed EPCs in group A were higher than those in group B at 1 h before surgery (37.24 ± 25.20 vs. 22.36 ± 12.26/ml; <s:math xmlns:s="http://www.w3.org/1998/Math/MathML" id="M10"><s:mi>P</s:mi><s:mo>=</s:mo><s:mn>0.034</s:mn></s:math> and 23.38 ± 15.30 vs. 13.12 ± 14.62/ml; <u:math xmlns:u="http://www.w3.org/1998/Math/MathML" id="M11"><u:mi>P</u:mi><u:mo>=</u:mo><u:mn>0.013</u:mn></u:math> , resp.). In addition, there were no obvious adverse reactions and no 30-day MACEs in both groups during the trial. Conclusion. SYD can reduce PMI and promote the mobilization of EPCs in the perioperative period of elective PCI in patients with UA.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) conducted an RCT in Unstable angina pectoris undergoing elective PCI (n=62). Shen-Yuan-Dan (SYD) vs. Conventional Western medicine treatment was evaluated on Incidence of periprocedural myocardial injury (PMI) (p=0.04). Shen-Yuan-Dan reduced the incidence of periprocedural myocardial injury compared to conventional treatment alone in patients with unstable angina undergoing elective PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: